Immupharma PLC Technology review published-Nature Communications
February 26 2019 - 1:02AM
RNS Non-Regulatory
TIDMIMM
Immupharma PLC
26 February 2019
RNS REACH 26 February 2019
ImmuPharma PLC
("ImmuPharma" or the "Company")
Technology review published in Nature Communications
ImmuPharma PLC (LSE: IMM), the specialist drug discovery and
development company is pleased to announce that on 25 February
2019, the peer reviewed research journal 'Nature Communications'
published a fundamental scientific publication on the proprietary
technology Urelix(TM) from UREkA Sarl ("Ureka"), ImmuPharma's
subsidiary.
Ureka, based at the IECB in Bordeaux, France, is carrying out
research into novel peptide molecules to generate drug candidates
for many diseases. The publication describes for the first time the
unique properties of oligourea foldamers as a tool to improve the
pharmaceutical properties of peptides. Further improvements not yet
described here are related to more focused medical indications. One
of the first focus areas has been GLP-1 analogues for the treatment
of Type II diabetes and NASH (Non-Alcoholic-Steato-Hepatitis) as
proof of concept for Ureka's technology.
Further applications of the Urelix(TM) technology include
protein/protein interactions, notably in cancer, and improvement of
marketed efficacious peptides allowing additional long lasting
patent protection, paving the way for a life cycle management
franchise. Novel patented technologies are also currently
implemented to cover other aspects of the improvement of peptides
including potential oral delivery.
The publication was entitled: "Peptide-oligourea hybrids
analogue of GLP-1 with improved action in vivo" and was authored by
a number of researchers working within Ureka including Dr Robert
Zimmer, ImmuPharma's Chief Scientific Officer and Dr Sébastien R.
Goudreau, Head of Research at Ureka.
Introduction to the Publication
Peptides have gained so much attention in the last decade that
they are now part of the main strategies, with small molecules and
biologics, for developing new medicines. Despite substantial
progress, the successful development of peptides as drugs still
requires a number of limitations to be addressed, including short
in vivo half-lives and poor membrane permeability.
Commenting, Dr Robert Zimmer, ImmuPharma's Chief Scientific
Officer, said: "I am very proud of the achievement of the research
team in Ureka since it started in 2014, having built a team of
skilled people and expanded our collaboration with the CNRS,
developing an exciting technology backed by a strong patent
portfolio. As such, a pleasing validation of years of research by
our scientific team and collaborators, giving us further confidence
in the long term potential of our Ureka platform."
Commenting, Dimitri Dimitriou, ImmuPharma's Chief Executive
Officer, said: "Natural peptides play key roles in human biological
processes and are effective and selective signaling molecules that
bind to specific receptors on cells. Using natural peptides as
drugs is not so effective because they are quickly broken down. To
put it simply, our technology overcomes these challenges and
represents an intelligent way to design novel drugs. The global
peptide therapeutics market achieved sales of $30 billion in
2018."
The full paper can now be downloaded from:
http://dx.doi.org/10.1038/s41467-019-08793-y or accessed via Nature
Communications website:
https://www.nature.com/search?q=immupharma.
For further information please contact:
ImmuPharma plc (www.immupharma.com) + 44 (0) 207 152 4080
Dimitri Dimitriou, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin +44 (0) 203 368 8974
Vassil Kirtchev
Stanford Capital Partners (Joint Broker)
Patrick Claridge, John Howes +44 (0) 203 815 8880
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
About Nature Communications
Nature Communications is an open access journal that publishes
high-quality research from all areas of the natural sciences.
Papers published by the journal represent important advances
of significance to specialists within each field. For more
information go to: https://www.nature.com
About the IECB
The Institut Européen de Chimie et Biologie (European
Institute of Chemistry and Biology) is an international and
interdisciplinary research team incubator, placed under the
joint authority of the CNRS, Inserm and the University of
Bordeaux. The CNRS is a public organization under the responsibility
of the French Ministry of Education and Research. The CNRS
is top of the Nature Index (The Nature Index ranks publication
productivity and is one indicator of global high-quality
research output ) and has over 31,000 staff and EUR3.2 bn
annual budget.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRASEAFWIFUSEFE
(END) Dow Jones Newswires
February 26, 2019 02:02 ET (07:02 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2024 to May 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From May 2023 to May 2024